This peptide is especially valued for its ability to enhance recovery from injury, reduce inflammation, and improve flexibility and endurance
Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively
Third-party testing protects consumers from three major risks: contamination (heavy metals, microbes, pesticides), mislabeling (wrong dose, wrong ingredient), and adulteration (undeclared stimulants or pharmaceuticals), says Smith
Without enough B12, people may experience fatigue, brain fog, or even nerve-related issues
Warning signs include severe, persistent abdominal pain that radiates to the back, nausea and vomiting that do not resolve, and tenderness in the upper abdomen